Looking into the prediagnostic phase of progressive supranuclear palsy

  • Wassilios G. Meissner
    Corresponding author. CRMR AMS, Hôpital Pellegrin, CHU Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux Cedex, France.
    Service de Neurologie, CRMR Atrophie Multisystématisée, CHU Bordeaux, 33000, Bordeaux, France
    Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France
    CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France
    Dept. Medicine, University of Otago, Christchurch, New Zealand
    New Zealand Brain Research Institute, Christchurch, New Zealand
    Search for articles by this author
  • Günter U. Höglinger
    German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
    Department of Neurology, Hannover Medical School, Hannover, Germany
    Search for articles by this author
      The early diagnosis of progressive supranuclear palsy (PSP) remains challenging. Early identification is not only important to inform patients and caregivers about the prognosis, but also for the enrollment of patients in early disease stages into disease-modification trials where treatments are expected to be the most effective, and for the development of new objective diagnostic tools (e.g. imaging, fluid biomarker).


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hoglinger G.U.
        • Respondek G.
        • Stamelou M.
        • Kurz C.
        • Josephs K.A.
        • Lang A.E.
        • et al.
        Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria.
        Mov. Disord. 2017; 32: 853-864
        • Grimm M.J.
        • Respondek G.
        • Stamelou M.
        • Arzberger T.
        • Ferguson L.
        • Gelpi E.
        • et al.
        How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
        Mov. Disord. 2019; 34: 1228-1232
        • Litvan I.
        • Agid Y.
        • Calne D.
        • Campbell G.
        • Dubois B.
        • Duvoisin R.C.
        • et al.
        Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.
        Neurology. 1996; 47: 1-9
        • Williams D.R.
        • Lees A.J.
        Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.
        Lancet Neurol. 2009; 8: 270-279
        • Rosler T.W.
        • Tayaranian Marvian A.
        • Brendel M.
        • Nykanen N.P.
        • Hollerhage M.
        • Schwarz S.C.
        • et al.
        Four-repeat tauopathies.
        Prog. Neurobiol. 2019; 180: 101644
        • Painous C.
        • Marti M.J.
        • Simonet C.
        • Garrido A.
        • Valldeoriola F.
        • Munoz E.
        • et al.
        Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study.
        Parkinsonism Relat. Disord. 2020; (In press)
        • Pont-Sunyer C.
        • Hotter A.
        • Gaig C.
        • Seppi K.
        • Compta Y.
        • Katzenschlager R.
        • et al.
        The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).
        Mov. Disord. 2015; 30: 229-237